Mark Rosenberg, MD, FASN, Dean, American University of the Caribbean School of Medicine
Mark Rosenberg is a nephrologist. As the dean of the American University of the Caribbean School of Medicine (AUC), Dr. Mark E. Rosenberg, MD, FASN, oversees the continuum of medical education, bringing with him innovative leadership that will greatly enhance the institution’s educational offerings and global impact. With over four decades of experience in medical practice, education, research, and leadership, Dr. Rosenberg’s role at AUC centers on advancing the school’s mission through international learning experiences and emphasizing social accountability and engagement.
Prior to his appointment at AUC, Dr. Rosenberg held significant positions at the University of Minnesota Medical School—including vice dean of education and academic affairs—where he pioneered new teaching methods and advocated for continuity of curriculum. His leadership extended to the Minneapolis VA Health Care System as chief of medicine and director of the Primary and Specialty Medicine service line, and he also served as director of the Division of Renal Diseases and Hypertension in the Department of Medicine.
Wade Bushman, MD, PhD., Senior Scientist, Department of Urology, University
of Wisconsin.
Dr. Bushman’s laboratory group studies molecular signaling in the mesenchymal-epithelial interactions of prostate development and reactivation of embryonic signaling pathways in prostatic neoplasia. Use mouse models, the Bushman lab is examing the role of Sonic hedgehog and BMP-4 signaling, which regulated prostate ductal budding.
Jose Lopez, MD (Lopez). Professor of Medicine, Division of Hematology University of Washington. Member, Bloodworks NW Research Institute
Dr. Lopez's primary research focus delves into platelet adhesion and von Willebrand factor functions. The laboratory has been involved for many years in studies aimed at understanding the basic mechanisms of platelet adhesion. Initially, these studies were aimed at the synthesis, assembly, posttranslational modifications and defining the ligand-binding sites of the receptor that mediates the first step of platelet adhesion, the glycoprotein (GP) Ib-IX-V complex. These studies are continuing, now focused on the association of the GP Ib-IX-V complex with membrane microdomains known as lipid rafts and downstream signaling after the complex has bound its primary adhesive ligand, von Willebrand factor (VWF), a multimeric polypeptide synthesized in endothelial cells and megakaryocytes.
Delores (Dorrie) J. Lamb, PhD. Director, Developmental Biology, Children's Mercy Kansas City
Dr. Lamb's research interests are in the fields of urology, male infertility, steroid hormone action, prostate cancer and genitourinary birth defects. Her experience is unique as she has an extensive background in both the clinical diagnostic and the basic science arenas in men's health as well as having a remarkable record of achievement in the mentoring
Robert Flaumenhaft, MD, PhD, Professor of Medicine Harvard Medical School, Division of Hemostasis and Thrombosis
Dr. Flaumenhaft received his M.D. and Ph.D. from NYU School of Medicine, completed a fellowship in Hematology/Oncology at Beth Israel Deaconess Medical Center (BIDMC), and received a M.M.Sc. from Harvard Medical School. He is currently a Professor at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis at BIDMC. His laboratory focuses on platelet and endothelial biology and mechanisms of thrombus formation. He also cares for patients with bleeding or clotting disorders. Dr. Flaumenhaft is Director of the T32 training program entitled, “Program in Blood Coagulation and Vascular Biology”. He also is Director of the BIDMC Organ-on-Chip Facility. He has previously served on or currently serves on several editorial boards in the field of Hemostasis and Thrombosis including Blood, JCI Insight, JTH, Thrombosis and Haemostasis , Thrombosis Research, and Seminars in Thrombosis and Hemostasis. He was Chairman of the Hemostasis and Thrombosis NIH Study Section, scientific co-chair of the ASH annual meeting and Chairman of the FASEB meeting on Functional Disulfide Bonds in Health and Disease. His work in in the field of Hemostasis and Thrombosis has earned him a Junior Faculty Award from the American Society of Hematology, a Career Award from the Burroughs Wellcome Fund, an Established Investigator Award from the American Heart Association, and an Outstanding Investigator Award from NIH. He was elected to the American Society for Clinical Investigation and to the Association of American Physicians. Dr. Flaumenhaft is also the founder of PlateletDiagnostics, a device company that specializes in the development of platelet function tests.